Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Cue Biopharma, Inc. - SIC # 2834 - PHARMACEUTICAL PREPARATIONS
Ticker
Exchange
SIC #
Website
Latest Ticker
CUE
Nasdaq
2834
www.cuebiopharma.com
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Cue Biopharma, Inc.
Cue Biopharma (CUE) Stock Fair Value Moves Lower As CUE 221 Debate Clouds Outlook
- Nov 20th, 2026 2:07 am
Analysts Turned Bearish on These 5 Stocks on Wednesday
- Nov 19th, 2026 8:21 am
This Company (10%+ Yield) Has a Giant Presence, But It Carries Giant Risks. Stay Away from the Value Trap.
- Nov 18th, 2026 12:15 pm
Cue Biopharma Reports Third Quarter 2026 Financial Results and Recent Business Highlights
- Nov 16th, 2026 2:48 pm
Cue Biopharma’s CUE-221 Hits Phase II Goals, Shows Durable CSU Response
- Sep 28th, 2026 3:02 am
Cue Biopharma (CUE) Reports Hives Drug Results. Can Longer Relief Set it Apart?
- Sep 25th, 2026 9:45 pm
An orexin drug’s ‘proof-of-concept’ in ADHD; Cue’s ‘unwarranted’ share slide
- Sep 22nd, 2026 8:17 am
Cue Biopharma Shares Jump 41.6% Premarket Following Phase 2 Trial Results
- Sep 21st, 2026 4:55 am
Cue Biopharma Announces Positive Topline Results from CUE-221 Phase 2 Study in Chronic Spontaneous Urticaria
- Sep 20th, 2026 4:00 am
Cue Biopharma Reports Second Quarter 2026 Financial Results and Recent Business Highlights
- Aug 14th, 2026 2:05 pm
Cue Biopharma Announces Appointment of James M. Ahlers as Chief Financial Officer and CUE-221 Investigational New Drug Submission
- Aug 3rd, 2026 6:30 am
3 Small-Cap Biotech Stocks Pairing Rapid Revenue Growth With High Insider Ownership
- Jul 23rd, 2026 11:56 pm
Head and Neck Squamous Cell Carcinoma Market is Projected to Boost at a CAGR of 10.5% During the Forecast Period (2026–2036) Due to the Launch of Emerging Novel Immunotherapies | DelveInsight
- Jul 13th, 2026 11:00 am
Cue Biopharma Appoints Dominic Borie, M.D., Ph.D., as Chief Medical Officer and Head of Research & Development
- Jul 13th, 2026 6:30 am
Cue Biopharma Announces $50.0 Million Private Placement
- Jul 9th, 2026 7:40 pm
Cue Biopharma Announces Board Transition and Addition of New Directors with Continued Company Evolution
- Jun 2nd, 2026 2:05 pm
Cue Biopharma to Present at the 2026 Jefferies Global Healthcare Conference
- May 21st, 2026 2:05 pm
Cue Biopharma Reports First Quarter 2026 Financial Results and Recent Strategic Developments
- May 14th, 2026 2:07 pm
Cue Biopharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- May 7th, 2026 5:07 pm
Cue Biopharma Announces $30 Million Private Placement
- Apr 30th, 2026 2:25 pm
Scroll